Onconetix, Inc.
- Open
- 0.77
- Day high
- 0.78
- Day low
- 0.75
- Prev close
- 0.79
- Volume
- 77K
- Mkt cap
- $9M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 0.7
- P/S
- 11.9
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$119K over the last 3 months (1 open-market buy, 3 sales)
- 🏛Institutions accumulating (13F)
Onconetix, Inc. (ONCO) is a Healthcare company listed on NASDAQ. The stock is down 100% over the past year. Over the trailing 3 months, insiders filed 1 open-market buy and 3 sales (SEC Form 4).
Onconetix, Inc. (ONCO) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
ONCO earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 13, 2026 | — | $-6.71 | — | $21457 | — |
| Mar 12, 2026 | — | $6.05 | — | $303596 | — |
| Nov 13, 2025 | — | $-6.25 | — | $303651 | — |
| Aug 14, 2025 | — | $-4.05 | — | $106494 | — |
| Jun 12, 2025 | — | $21.19 | — | $101630 | — |
| Dec 9, 2024 | — | $-2.24 | — | $406859 | — |
| Aug 29, 2024 | — | $-9.20 | — | $704848 | — |
| May 20, 2024 | $-8.40 | $-6.40 | +23.8% | $700433 | +1107.6% |
| Mar 9, 2024 | — | $-1.00 | — | $58465 | — |
| Nov 17, 2023 | $-0.19 | $-0.28 | -47.4% | — | — |
ONCO insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Apr 22, 2026 | HRT FINANCIAL LP10 percent owner | Sell | 49,710 | $0.69 |
| Apr 21, 2026 | HRT FINANCIAL LP10 percent owner | Sell | 53,867 | $0.73 |
| Apr 21, 2026 | HRT FINANCIAL LP10 percent owner | Sell | 94,462 | $0.75 |
| Apr 21, 2026 | HRT FINANCIAL LP10 percent owner | Buy | 34,636 | $0.73 |
| Apr 16, 2026 | HRT FINANCIAL LP10 percent owner | Buy | 92,554 | $0.76 |
| Apr 16, 2026 | HRT FINANCIAL LP10 percent owner | Buy | 74,350 | $0.77 |
| Aug 19, 2025 | Oakley Andrew Johndirector | Grant | 618 | — |
| Aug 19, 2025 | Tarsh Simondirector | Grant | 618 | — |
| Aug 19, 2025 | Meier Thomasdirector | Grant | 618 | — |
| Aug 19, 2025 | Ramdeen Timothy R.director | Grant | 618 | — |
| Mar 25, 2025 | Oakley Andrew Johndirector | Grant | 1,709 | — |
| Jan 22, 2025 | Schiess Ralphofficer: Interim CEO, CSO | Grant | 177,462 | — |
| Jan 22, 2025 | Bruhlmann Christianofficer: Chief Strategy Officer | Grant | 177,462 | — |
| Sep 30, 2024 | SINGH AJITdirector | Grant | 3,318 | — |
| Sep 30, 2024 | Tarsh Simondirector | Grant | 3,318 | — |
Source: ONCO SEC Form 4 filings, latest Apr 22, 2026. For informational purposes only — not investment advice.
See the full ONCO insider & 13F page →Onconetix, Inc. company profile
Overview
Onconetix, Inc. (NASDAQ:ONCO) is a biotechnology and pharmaceutical company founded in 2018 and headquartered in Cincinnati, Ohio. Originally incorporated as Blue Water Biotech, Inc., the company changed its name to Onconetix in December 2023. The company went public in February 2022 and focuses on developing and commercializing transformational therapies to address various health challenges worldwide. Onconetix operates in the biotechnology sector with a dual focus on commercializing existing FDA-approved treatments and developing innovative vaccine candidates for infectious diseases.
Business
Onconetix operates in the biotechnology and pharmaceutical industry, which involves the research, development, and commercialization of medical treatments and vaccines. The company has two primary business segments that represent distinct approaches to healthcare innovation. The first segment centers around Entadfi, an FDA-approved once-daily pill that combines two existing medications: finasteride and tadalafil. This combination therapy treats benign prostatic hyperplasia (BPH), a common condition where the prostate gland enlarges and can cause urinary problems in men. Finasteride works by blocking the hormone that causes prostate growth, while tadalafil helps relax muscles in the prostate and bladder. By combining these two well-established drugs into a single pill, Entadfi offers patients convenience and potentially improved compliance compared to taking separate medications. The second segment focuses on vaccine development for infectious diseases. Onconetix is developing a streptococcus pneumoniae vaccine candidate designed to prevent middle ear infections in children and pneumonia in elderly patients. Streptococcus pneumoniae is a bacteria that causes serious infections, particularly dangerous for young children and older adults with weakened immune systems. The company is also working on a universal flu vaccine that aims to provide broader protection against multiple influenza strains, potentially eliminating the need for annual flu shots that target only specific predicted strains. Additionally, Onconetix has licensed a novel norovirus S&P nanoparticle vaccine platform from Cincinnati Children's Hospital. This versatile virus-like particle technology serves as a foundation for developing vaccines against multiple infectious diseases, including Marburg virus and monkeypox. Virus-like particles mimic the structure of viruses but lack genetic material, making them safe while still triggering immune responses. Based on recent financial data, the commercialized Entadfi product generates the majority of current revenue, while the vaccine development programs represent the company's future growth potential but are still in various stages of clinical development.
Revenue model
Onconetix generates revenue through two distinct business models. The primary current revenue source comes from product sales of Entadfi, the FDA-approved combination therapy for benign prostatic hyperplasia. The company sells this pharmaceutical product through traditional pharmaceutical distribution channels to healthcare providers and patients, generating revenue of approximately $700,000 per quarter in recent periods. The paying customers for Entadfi include healthcare systems, pharmacies, and ultimately patients who use insurance or pay out-of-pocket for the medication. The second business model involves licensing and partnership agreements for vaccine development programs. While these programs are not yet generating significant revenue, they represent potential future income streams through licensing deals, milestone payments from pharmaceutical partners, and eventual product sales if the vaccines successfully complete clinical trials and receive regulatory approval. Several factors could significantly impact Onconetix's margins and profitability. Positive margin drivers include successful market penetration of Entadfi, which could benefit from the growing aging male population and increased awareness of combination therapies for BPH. The company's vaccine programs could generate substantial returns if they successfully complete clinical trials, as vaccine markets often command premium pricing, especially for novel approaches like universal flu vaccines or emergency-use vaccines for outbreak diseases. Negative margin pressures include the high costs associated with clinical trials and regulatory approval processes for the vaccine candidates, which require substantial ongoing investment with uncertain outcomes. The pharmaceutical industry faces increasing pricing pressure from insurance companies and government healthcare programs, which could limit Entadfi's pricing power. Additionally, competition from generic alternatives or new combination therapies could erode market share. The company's small scale means it lacks the manufacturing and distribution efficiencies of larger pharmaceutical companies, potentially resulting in higher per-unit costs. Regulatory setbacks or clinical trial failures for any of the vaccine programs would represent significant sunk costs and could impact investor confidence and access to future funding.
Competitive moat
Onconetix operates in a highly competitive biotechnology landscape with limited sustainable competitive advantages. The company's primary moat around Entadfi is relatively narrow, as the product combines two existing, well-known medications (finasteride and tadalafil) rather than representing a novel therapeutic breakthrough. While the FDA approval and specific combination formulation provide some regulatory protection, this moat could be eroded by generic competition once patents expire or by competitors developing similar combination therapies. The vaccine development programs represent a potentially stronger but unproven moat. The licensed norovirus vaccine platform technology from Cincinnati Children's Hospital provides some intellectual property protection and technical expertise that competitors would need to replicate or work around. However, the vaccine development field is intensely competitive, with major pharmaceutical companies possessing significantly greater resources for research, clinical trials, and regulatory processes. The company's small size and limited resources represent a significant competitive disadvantage rather than a moat. Large pharmaceutical companies like Pfizer, Merck, or Johnson & Johnson have vastly superior financial resources, established relationships with regulatory agencies, extensive clinical trial networks, and global distribution capabilities. These larger competitors can more easily absorb the risks and costs associated with drug development failures. Potential disruption and competition could come from multiple sources. For Entadfi, competition includes existing separate prescriptions of finasteride and tadalafil, other BPH treatments, and potentially new combination therapies from larger pharmaceutical companies. In the vaccine space, major pharmaceutical companies are actively developing universal flu vaccines and other infectious disease vaccines, with significantly more resources and expertise. Additionally, emerging biotechnology companies with novel vaccine platforms or delivery mechanisms could potentially leapfrog Onconetix's development programs. The company's competitive position is further weakened by its dependence on external partnerships and licensing agreements, which limits its control over key technologies and potential revenue streams. Overall, Onconetix operates with minimal sustainable competitive advantages in highly competitive markets dominated by much larger, better-resourced competitors.
Risks & safety
Onconetix presents significant financial risks with minimal margin of safety for investors. **Cash Burn and Solvency Risk:** - Current cash position of $341,495 as of Q3 2024, down dramatically from $4.5 million in Q1 2024 - Quarterly cash burn of approximately $1.1-3.2 million based on operating cash flows - Current ratio of 0.06, indicating severe liquidity constraints with current assets of $1.0 million against current liabilities of $17.4 million - The company faces immediate solvency risk and will likely need emergency financing within months **Debt and Capital Structure:** - Total liabilities of $20.9 million against total assets of $61.9 million - Debt-to-equity ratio of 0.30, which is manageable but concerning given the cash position - Negative working capital of approximately $16.3 million **Valuation Metrics:** - Trading at 0.20x book value, suggesting market skepticism about asset values - Negative enterprise value due to financial distress - Revenue of only $406,859 in Q3 2024, insufficient to cover operating expenses **Other Considerations:** - Minimal revenue base relative to operating expenses creates high cash burn risk - Clinical-stage vaccine programs require substantial additional investment with uncertain outcomes - Small market capitalization of approximately $3.3 million limits access to capital markets
Recent development
Based on the available financial data, Onconetix has undergone significant strategic developments over recent years, though detailed earnings call transcripts are not available to provide comprehensive insights into management's strategic communications. The most notable recent development was the corporate rebranding from Blue Water Biotech to Onconetix in December 2023, which appears to reflect a strategic repositioning of the company's identity and focus. This name change coincided with the company's evolution from a pure development-stage biotechnology company to one with a commercialized product. The company's commercialization of Entadfi represents a significant milestone, transitioning from zero revenue in 2022 to generating quarterly revenues of approximately $400,000-700,000 throughout 2024. This FDA-approved combination therapy for benign prostatic hyperplasia provides the company with its first meaningful revenue stream and validates its ability to bring products to market. In terms of pipeline development, Onconetix has expanded its vaccine portfolio through strategic licensing agreements, most notably acquiring the norovirus S&P nanoparticle vaccine platform from Cincinnati Children's Hospital. This platform technology provides a foundation for developing vaccines against multiple infectious diseases, including high-priority targets like Marburg virus and monkeypox, potentially positioning the company to respond to future pandemic or outbreak scenarios. The company has also been advancing its streptococcus pneumoniae vaccine candidate and universal flu vaccine programs, though specific clinical trial progress and timelines are not detailed in the available financial statements. These programs represent the company's longer-term growth strategy beyond the current Entadfi revenue base. However, the financial trajectory shows concerning trends, with the company burning through cash reserves rapidly while struggling to scale Entadfi revenues sufficiently to achieve profitability. The dramatic decline in cash position from $4.5 million in Q1 2024 to $341,495 in Q3 2024 suggests the company may be facing operational challenges or increased development costs that are straining its financial resources.
ONCO company profile · for informational purposes only — not investment advice.
Track ONCO with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free